Y-Intercept (HK)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Y-Intercept (HK)’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,756	Closed	-$248K	–	1819
2023 Q1	$248K	Sell	8,756 -1,351	-13%	-$40.1K	0.03%	860
2022 Q4	$295K	Buy	+10,107	New	+$321K	0.04%	661

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Y-Intercept (HK)'s EGRX Position: Q2 2023 in Review

Y-Intercept (HK) sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 8,756 shares — an estimated $248K sold.

Y-Intercept (HK) first reported a position in EGRX in Q4 2022 and held it in 2 quarters. The position peaked at $295K in Q4 2022. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

Y-Intercept (HK) reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Y-Intercept (HK) sold 8,756 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $248K.
Y-Intercept (HK) first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2022 and held it in 2 quarters.
Y-Intercept (HK)'s Eagle Pharmaceuticals, Inc. position peaked at $295K in Q4 2022.
126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Y-Intercept (HK)'s 13F filing for Q2 2023, filed 14 Aug 2023.